Liquid biopsies research represent a cutting-edge approach in oncology research, offering minimally invasive methods to detect and monitor cancer through blood tests. This category covers research on how liquid biopsies work, their advantages over traditional tissue biopsy, and their application in cancer diagnosis and treatment. As a vital subset of biomedical and clinical sciences focused on carcinogenesis, this field advances cancer detection and personalized medicine. JoVE Visualize enhances learning by pairing PubMed articles with JoVE’s experiment videos to help researchers and students grasp critical experimental techniques and findings.
Key Methods & Emerging Trends
Core Methods in Liquid Biopsies
Established methods in liquid biopsies primarily involve the isolation and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles from blood samples. Conventional techniques include polymerase chain reaction (PCR)-based assays and next-generation sequencing (NGS), enabling detection of genetic mutations linked to cancer. These procedures help researchers understand tumor dynamics non-invasively and facilitate real-time monitoring of treatment responses. Liquid biopsy procedures often offer benefits over tissue biopsies by reducing patient discomfort while maintaining diagnostic value.
Emerging and Innovative Approaches
Recent advances are focusing on enhancing the sensitivity and specificity of liquid biopsy tests for cancer through integrated multi-omics analyses and machine learning algorithms. Novel platforms aim to reduce liquid biopsy costs and improve detection of rare biomarkers in blood. Research increasingly explores combining liquid biopsy blood tests with imaging and other clinical data to better predict cancer progression. Additionally, innovations such as microfluidic devices and single-cell sequencing are expanding capabilities, addressing some disadvantages of liquid biopsy by refining sample processing and molecular characterization.